Recent studies show that left DLPFC stimulation induces acute and persistent changes in the subgenual anterior cingulate cortex (sgACC), and the degree of sgACC modulation predicts treatment response in patients. To understand how theta-burst stimulation (TBS) over the left DLPFC influences sgACC microcircuitry, we applied spectral dynamic causal modeling (DCM) with a conductance-based canonical microcircuit model (CMM-NMDA) to resting-state EEG data acquired at 2, 15, and 30 minutes following continuous TBS (cTBS), intermittent TBS (iTBS), and sham stimulation. Using a multilevel parametric empirical Bayes framework, we observed that cTBS induce wider network effect 2 min after stimulation while iTBS induce more lasting changes up to 30 min following stimulation. Unlike sham, both TBS protocols induced a transient reduction in NMDA-dependent effective connectivity from right DLPFC to left sgACC. Crucially, TBS produced sustained inhibition within left sgACC microcircuits, characterized by increased self-inhibition of spiny-satellite cells. Together, these findings demonstrate that spectral DCM can resolve the dynamic, hierarchical neuromodulatory effects of TBS in healthy brains and highlight a potential mechanism underlying the antidepressant action of left DLPFC TBS.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://doi.org/10.25452/figshare.plus.c.5910329

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes